BackAbeona Therapeutics Overview

Abeona Therapeutics Total Liabilities

Track Abeona Therapeutics's total liabilities ($54M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$53.55M
7.61% YoYΔ $-4.41M vs prior year quarter

Peer average

Loading

Abeona Therapeutics Total Liabilities History

Loading

Abeona Therapeutics vs. peers: Total Liabilities Comparison

Loading

Abeona Therapeutics Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Abeona Therapeutics (ABEO) FAQ

The latest total liabilities for ABEO is $54M as of March 2026. That compares with $58M in the prior-year period — down 7.6% year over year. Investors often review this figure alongside Abeona Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ABEO's total liabilities moved from $58M to $54M — a 7.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Abeona Therapeutics's operating scale or balance-sheet position.

A total liabilities figure of $54M for ABEO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ABEO's total liabilities ($54M), review year-over-year change from $58M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Abeona Therapeutics's total liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.